Toho Holdings Co., Ltd.
Stock Price Chart
2026/06/11 UpdatedPrice Trend
2026/06/11 UpdatedPrice & Trading Details
2026/06/11 UpdatedPRICE
TRADING
Analyst Recommendations 3 analysts
Updated 2026/06/01Earnings Calendar
Updated 2026/06/01Recent Earnings
| Date | EPS Est. | EPS Actual | Surprise |
|---|---|---|---|
| 2026/05/13 | ¥66.21 | ¥44.13 | -33.4% |
| 2026/02/11 | ¥117.06 | ¥127.93 | +9.3% |
| 2025/08/05 | ¥28.82 | ¥53.61 | +86.0% |
Shareholder Composition
Updated 2026/06/01Dividend History 4Years Growth
Updated 2026/06/04| Year | Dividend | Change |
|---|---|---|
| 2026 | ¥120 | +41.2% |
| 2025 | ¥85 | +80.9% |
| 2024 | ¥47 | +38.2% |
| 2023 | ¥34 | +9.7% |
| 2022 | ¥31 | - |
Financial Performance
2026/06/04 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥1,266,171M | ¥1,392,117M | ¥1,476,712M | ¥1,518,495M |
| Gross Profit | ¥108,687M | ¥114,366M | ¥119,148M | ¥121,648M |
| Operating Income | ¥12,534M | ¥16,369M | ¥19,337M | ¥18,942M |
| Pretax Income | ¥20,186M | ¥20,492M | ¥30,845M | ¥28,102M |
| Net Income | ¥13,379M | ¥13,630M | ¥20,657M | ¥19,844M |
| EPS | ¥174.48 | ¥180.67 | ¥286.79 | ¥284.22 |
| Operating Margin | 0.99% | 1.18% | 1.31% | 1.25% |
| Balance Sheet | ||||
| Total Assets | ¥702,376M | ¥715,288M | ¥773,427M | ¥722,805M |
| Total Equity | ¥241,079M | ¥242,823M | ¥249,330M | ¥256,779M |
| Total Liabilities | ¥461,297M | ¥472,465M | ¥524,097M | ¥466,026M |
| Cash | ¥94,256M | ¥86,201M | ¥132,970M | ¥86,533M |
| Interest-bearing Debt | ¥40,737M | ¥37,888M | ¥30,244M | ¥21,260M |
| Equity Ratio | 34.32% | 33.95% | 32.24% | 35.53% |
| D/E Ratio | 0.17 | 0.16 | 0.12 | 0.08 |
| Cash Flow | ||||
| Operating CF | ¥16,341M | -¥9M | ¥59,934M | -¥26,675M |
| Investing CF | -¥11,032M | ¥4,315M | ¥9,091M | -¥4,180M |
| Financing CF | -¥4,473M | -¥13,060M | -¥22,195M | -¥20,364M |
| Free CF | ¥12,139M | -¥2,528M | ¥56,153M | -¥32,432M |
| Efficiency | ||||
| ROE | 5.55% | 5.61% | 8.29% | 7.73% |
| ROA | 1.90% | 1.91% | 2.67% | 2.75% |
Latest IR Information
-
Financial Summary for the Fiscal Year Ending March 2026 [Japanese Standards] (Consolidated)
For the fiscal year ending March 2026, consolidated net sales were ¥1,553,364 million (up 2.3% YoY), operating profit was ¥166,010 million (down 12.3% YoY), and net income attributable to owners of the parent was ¥173,270 million (down 12.7% YoY).
Read more -
Notice of Adjustment to Conversion Price of 2028 Maturity Euro Yen Convertible Bonds
The conversion price of our 2028 maturity Euro Yen convertible bonds will be adjusted after April 1, 2026, from 2,760.1 yen to 2,690.2 yen. The adjustment is based on the resolution of the Board of Directors held on May 13,...
Read more -
Notice Regarding the Determination of Director Candidates and CEO Candidate
For the ordinary general meeting of shareholders scheduled on June 26, 2026, director candidates and the CEO candidate have been determined. The structure includes one newly appointed external director, aiming to execute the new medium-term management plan.
Read more -
Notice Regarding the Board of Directors' Evaluation of the Large-Scale Purchase of Our Company's Shares and the Proposal of a Shareholders' Resolution on the Activation of Countermeasures
In response to the large-scale purchase of Toho Holdings shares by 3D Investment Partners, the Board resolved to activate countermeasures due to concerns over impairment of corporate value, with the proposal scheduled to be submitted at the June 2026 shareholders...
Read more
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥4,525
Rating Score: 3.00 (Based on 3 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Toho Holdings Co., Ltd. engages in the wholesale distribution of pharmaceutical products in Japan. It operates in four segments: Pharmaceutical Wholesale Business, Dispensing Pharmacy Business, Pharmaceutical Manufacturing and Sales Business, and Other Peripheral Businesses. The company sells pharmaceuticals, narcotics, reagents, and medical devices to hospitals, clinics, and dispensing pharmacies. It is also involved in the management of the dispensing pharmacies business; operates health insurance pharmacy; provision of support home medical care services; peripheral businesses; core system operations; and real estate agency business. In addition, the company manufacture and sell pharmaceuticals; sells generic drugs; and manufactures injection drugs on consignment. Further, it provides support services, including the development and sale of customer support systems, assistance in the start-up of medical institutions and pharmacies, management consulting services, medical support, and personnel recruitment. Additionally, the company offers various customer support systems, including ENIF, an information terminal for pharmaceutical ordering; ENI-Pharmacy, a support system for the separation of dispensing and prescribing functions; LXMATE Helios a medical care appointment system; KAITOS, an online medical consultation and medication guidance system; ENIFwin Nex-Sus, an inventory control system for large hospitals ENIFvoice SP/ ENIFvoice SP + A/ ENIFvoice Core, a supporting system for electronic medication history recording with voice recognition. The company was incorporated in 1948 and is headquartered in Chuo, Japan.